Related Experiment Video

Updated: Sep 13, 2025

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.1K

BUB1 an Overexpressed Kinase in Sarcoma: Finding New Target Therapy for Osteosarcoma, Liposarcoma, Synovial Sarcoma,

Mercedes Olvera-Valencia1,2, Fernando Luna-Maldonado3, Joselyn Juarez-Reyes2,4

  • 1Programa Institucional de Biomedicina Molecular, Escuela Nacional de Medicina y Homeopatía del IPN, Guillermo Massieu Helguera #239 Fracc. La escalera, Ticoman 07320, Ciudad de Mexico, Mexico.

Biomolecules
|July 29, 2025
PubMed

Insights

Researchers identified BUB1 kinase as a common target in four major sarcoma types. Inhibiting BUB1 shows promise for reducing tumor growth and improving patient survival in bone and soft tissue sarcomas.

Area of Science:

  • Oncology
  • Molecular Biology
  • Bioinformatics

Background:

  • Sarcomas are complex mesenchymal tumors with limited effective treatments.
  • Current sarcoma therapies often exhibit high toxicity and low efficacy.
  • Identifying novel therapeutic targets is crucial for improving sarcoma patient outcomes.

Purpose of the Study:

  • To identify commonly overexpressed kinases across four frequent sarcoma subtypes.
  • To establish novel therapeutic targets for sarcoma treatment.
  • To investigate the role of BUB1 (Budding Uninhibited by Benzimidazole 1) as a potential therapeutic target.

Main Methods:

  • Bioinformatic analysis of patient-derived gene expression data.
  • Identification of overexpressed kinases in osteosarcoma, liposarcoma, leiomyosarcoma, and synovial sarcoma.
  • Molecular and functional assays, including pharmacological inhibition of BUB1 in sarcoma cell lines.

Main Results:

  • BUB1 was consistently overexpressed across the four studied sarcoma subtypes.
  • Pharmacological inhibition of BUB1 reduced AKT and H2A phosphorylation.
  • BUB1 inhibition effectively decreased sarcoma cell proliferation and colony formation.
  • High BUB1 expression correlated with poorer overall survival in sarcoma patients.

Conclusions:

  • BUB1 is a promising therapeutic target and prognostic marker for sarcomas.
  • Targeted inhibition of BUB1 may offer a new strategy for sarcoma treatment.
  • Further research into BUB1 inhibition could improve outcomes for bone and soft tissue sarcoma patients.
Keywords:
bone sarcomakinasessarcomasoft tissue sarcomastherapeutic target

More Related Videos

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate07:31

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

3.8K
Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models04:25

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models

Published on: October 28, 2021

9.9K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.8K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
5.4K